Many of the ocular endpoint problems 20/20 Onsite is called in to fix start in the protocol, long before the first participant sits down for an eye exam. A vague best-corrected visual acuity (BCVA) procedure, a missing optical coherence tomography (OCT) scan specification, or a visit window that ignores dilation can surface months later as deviations, rescans, or an amendment. Designing ocular assessment endpoints with ophthalmic input at the protocol stage prevents many of those problems before they start. Here is how sponsors can define approvable endpoints, match assessments to them, and use protocol consultation to keep amendments off the timeline.
Key Takeaways
On This Page
A common failure point is a protocol that names the assessment but not the conditions that make it repeatable. BCVA scores shift with chart distance, lighting, and refraction method. OCT measurements shift with device model and scan protocol. When those details are left to each site, the same endpoint gets measured several different ways.
Fixing that after enrollment starts is slow and costly. A 2024 Tufts Center for the Study of Drug Development (CSDD) analysis found that 76% of Phase 1 to 4 protocols now have at least one amendment, up from 57%, with an average of 3.3 amendments per protocol. The same study found that moving from the need to amend to final oversight approval takes an average of 260 days, and sites operate on different protocol versions for an average of 215 days.
For a trial with ophthalmic endpoints, 215 days of mixed versions can mean mixed assessment methods inside one dataset. Tufts classified most amendments as unavoidable, with regulatory agency requests among the top reasons. Protocols cannot prevent every change, but they can make sure the ophthalmic plan is specific enough to hold steady and flexible enough to absorb one.
If your protocol is still in draft, this is the lowest-cost point to fix it. Request a Protocol Review with 20/20 Onsite's clinical team.
An approvable ocular endpoint measures a clinically meaningful change in visual function, or a structural marker with evidence that it predicts one. FDA and National Eye Institute (NEI) discussions treat visual function as the anchor, with anatomical measures in a supporting role unless they are validated. Settle this hierarchy before choosing a single assessment.
Three reference points shape most designs:
Surrogate endpoints open another regulatory path. FDA's accelerated approval program allows drugs for serious conditions with unmet need to be approved based on a surrogate endpoint, a marker thought to predict clinical benefit. For gene therapy and inherited retinal disease programs, decide early which exploratory endpoints you will collect with the same rigor as the primary endpoint.
Start with the endpoint, then choose the fewest assessments that measure it reliably and keep patients safe. The right mix depends on the therapeutic area and on whether the eye is the target organ or a safety concern.
| Therapeutic Area | Typical Endpoint Focus | Core Assessments |
|---|---|---|
| Retina: neovascular AMD, diabetic macular edema (DME), retinal vein occlusion | Change in BCVA, with retinal thickness as supporting evidence | BCVA, OCT, fundus photography |
| Diabetic retinopathy: non-proliferative (NPDR) and proliferative (PDR) | Progression or regression of retinopathy severity | Fundus photography, OCT, BCVA |
| Geographic atrophy | Lesion growth over time | Fundus imaging, OCT, BCVA |
| Glaucoma and ocular hypertension | IOP reduction and visual field progression | IOP, visual fields, OCT of the optic nerve, slit lamp examination |
| Gene therapy and inherited retinal disease | Visual function, often paired with exploratory measures | BCVA, visual fields, OCT, fundus photography |
| Non-ophthalmic trials | Ocular toxicity and safety monitoring | BCVA, IOP, slit lamp examination, dilated fundus exam, OCT |
Non-ophthalmic programs deserve the same rigor. When a drug class carries a known or suspected ocular risk, baseline exams must be captured exactly the way follow-ups will be, or a real safety signal becomes hard to separate from measurement noise. Slit lamp examination, for example, is a standard way to document anterior segment inflammation such as iritis. Our review of GLP-1 clinical trial eye safety shows how this plays out in practice.
Protocol consultation brings ophthalmic specialists into the draft to test each assessment against the endpoint, the visit schedule, and site capacity. 20/20 Onsite's Protocol Review aligns ocular assessments with study endpoints, validates compliance, and reduces risk across multi-center studies. Here is what that looked like when sponsors brought 20/20 Onsite in.
"A protocol tells a site what to measure. It rarely tells them how to measure it the same way at month 12 as at baseline, and that gap is where most of our protocol review time goes." Dr. David Gibson, OD, Chief Clinical Officer, 20/20 Onsite.
Work through these steps before the protocol is final. Each one closes a gap that commonly becomes a deviation or an amendment.
Define primary, secondary, and exploratory endpoints, and tie each to a specific assessment.
Name the chart, test distance, lighting, refraction method, OCT device and scan protocol, and IOP method.
Complete BCVA before dilating drops and plan for fatigue during long imaging sessions.
Require technician certification, calibration records, and image review before the participant leaves.
Confirm equipment, staff, and capacity at each site, or plan a point-of-need option.
Decide how assessments will scale if a regulator adds an ocular safety requirement mid-study.
Leaner, better-sequenced visits also improve the patient experience, which supports retention. 20/20 Onsite reports 91% patient retention against a 70% industry standard.
Endpoint quality is decided at the protocol stage, not at the first visit. 20/20 Onsite delivers BCVA, IOP, OCT, visual fields, slit lamp biomicroscopy, and fundus photography at the point of need, with a 98% data submission accuracy rate. Its Protocol Review aligns those assessments with your endpoints before a single site is activated.
Request a Protocol Review to have our clinical team assess your draft.
Protect Your Ocular Endpoints Before Site Activation
Have 20/20 Onsite's clinical team review your draft protocol and align every ophthalmic assessment with your endpoints.
Request a Protocol ReviewA specialized ophthalmic trial partner can review your protocol and align ocular assessments with your endpoints before site activation. 20/20 Onsite is the only provider exclusively dedicated to ophthalmic assessments for clinical research. Its Protocol Review covers endpoint alignment, assessment specifications, and multi-center risk, and the same team then performs those assessments through Mobile Vision Clinics, Mobile Vision Pods, and Mobile Clinic Suites. Request a Protocol Review to start.
How Do You Align Ophthalmic Assessments With Study Endpoints When Writing a Trial Protocol?Start from the endpoint hierarchy, assign each endpoint the assessment that measures it, and write down exactly how that assessment is performed. For a BCVA endpoint, that means the chart, distance, lighting, and refraction method. For OCT, it means the device model and scan protocol. Any assessment that maps to neither an endpoint nor a safety need is a candidate for removal. Our guide to BCVA, OCT, and IOP testing in clinical trials covers each method in more depth.
How Can Sponsors Avoid Protocol Amendments Related to Ophthalmic Assessments?Bring ophthalmic specialists into protocol drafting, specify every assessment in detail, and confirm site feasibility before activation. Many amendments stem from regulatory requests that no sponsor can prevent, so the ophthalmic plan should also be able to scale if an ocular safety requirement is added mid-study. The ophthalmic protocol risk self-assessment helps teams spot weak points early.
What Change in Best Corrected Visual Acuity Is Considered Clinically Meaningful?A 3-line (15-letter) change is the long-standing benchmark for clinical significance, according to the NEI/FDA endpoints symposium report. A between-group difference of 15 letters or more is also considered clinically significant. Smaller changes can be acceptable when treatment risk is low, so confirm the threshold with FDA during protocol development.
Can OCT Serve as a Primary Endpoint in Ophthalmology Trials?OCT most often serves as a secondary, supporting, or exploratory endpoint. NEI/FDA discussions note that OCT findings do not always correlate with visual function, and sponsors using retinal thickness in AMD trials must show an associated change in vision. OCT remains essential for eligibility, safety monitoring, and structural analysis in retina and glaucoma programs.
Do Non-Ophthalmic Trials Need Ocular Assessments?Yes, when a drug class carries a known or suspected ocular risk, or when a regulator requests ocular safety data. Baseline and follow-up BCVA, IOP, slit lamp examination, and dilated fundus exams document ocular toxicity in a way reviewers can trust. Read more on why eye exams matter in non-ophthalmic trials.
When Should a Sponsor Schedule an Ophthalmic Protocol Review?Schedule it before the protocol is finalized and ideally before site selection, when endpoint and feasibility changes cost the least. 20/20 Onsite also supports studies already underway, including mid-trial protocol changes that add ophthalmic assessments across dozens of sites.
How Do You Balance Patient Engagement With Regulatory Compliance in Ocular Assessments?Reduce the burden on patients without changing how assessments are performed. Point-of-need delivery brings the same calibrated equipment and trained ophthalmic clinicians to each participant, so visits get easier while protocol standards stay fixed. Cutting redundant assessments during protocol review helps both goals at once.